Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success

Viking Therapeutics' VK2735 oral trial met efficacy and safety endpoints, yet high discontinuation rates and modest weight loss disappointed Wall Street, triggering a steep sell-off in VKTX shares. Despite underperforming leading competitors like Novo Nordisk and Eli Lilly, VK2735 remains a top-three candidate in the rapidly expanding obesity market. The market's focus now shifts to the more decisive Phase 3 injectable VK2735 data, suggesting a potential recalibration of expectations for weight loss drug efficacy.

Analysis

Viking Therapeutics (VKTX) experienced a significant stock sell-off following the release of its oral VK2735 trial data. While the trial successfully met its primary efficacy and safety endpoints, the results were viewed as underwhelming by the market, particularly regarding high discontinuation rates and modest weight loss figures when benchmarked against established oral GLP-1 drugs from competitors Eli Lilly and Novo Nordisk. Despite this negative market reception, the article frames VK2735 as a top-three candidate within the large and rapidly expanding obesity treatment market. The focus has now shifted to the forthcoming Phase 3 data for the injectable version of VK2735, which is positioned as a more decisive catalyst for the company's valuation. The author presents a contrarian bullish outlook, suggesting the market's expectations for weight loss drug efficacy may require a downward revision and that the current price dislocation presents a long-term buying opportunity, underscored by potential M&A interest if the drug program achieves even partial market penetration.

Key Decisions for Investors

• Investors should evaluate the current discounted share price as a potential high-risk entry point, with the investment thesis now heavily dependent on the success of the upcoming Phase 3 injectable trial data.
• The pivotal catalyst for Viking Therapeutics is now the injectable VK2735 program, and positions should be managed in anticipation of this more decisive data release.
• Consider the company's long-term M&A potential, as capturing even a small portion of the vast obesity market could make it a strategic acquisition target for larger pharmaceutical players, providing a potential floor for valuation.